Products
Isecarosmab Biosimilar Bispecific Single-Domain Antibody (ADAMTSL5 × Albumin) for Research
Pre-Made Isecarosmab biosimilar, Bispecific Single Domains (VH-VH'), Anti-ADAMTSL5;ALB Antibody: Anti-THSD6;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-281-1mg | 1mg | |
| GMP-Bios-ab-281-10mg | 10mg | |
| GMP-Bios-ab-281-100mg | 100mg | |
| GMP-Bios-ab-281-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Isecarosmab biosimilar, Bispecific Single Domains (VH-VH'), Anti-ADAMTSL5;ALB Antibody: Anti-THSD6;FDAHT/HSA/PRO0883/PRO0903/PRO1341 therapeutic antibody |
| INN Name | Isecarosmab |
| Target | ADAMTSL5;ALB |
| Format | Bispecific Single Domains (VH-VH') |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na;na |
| VD LC | na;na |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Merck |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Development Tech | na |
About target - ADAMTSL5
1. Protein ADAMTS-like protein 5
2. Gene ADAMTSL5
3. Organism Homo sapiens (Human)
Function
May play a role in modulation of fibrillin microfibrils in the extracellular matrix (ECM).
Caution
Although strongly similar to members of the ADAMTS family it lacks the metalloprotease and disintegrin-like domains which are typical of that family.
